Biotron presents HIV trial data at IAS 2013
03 July, 2013 by Dylan Bushell-EmblingBiotron (ASX:BIT) has presented trial data at International AIDS Society 2013 showing BIT225’s potential to target HIV reservoir cells and cross the blood-brain barrier.
Researching sexual health in Indigenous Australian men
27 June, 2013A PhD scholarship for Aboriginal and Torres Strait Islander students has been created by Andrology Australia.
Strategic Research Priorities
26 June, 2013In a whole-of-government approach to investing in research, the Australian Government announced 15 Strategic Research Priorities (SRPs) this week.
Prima to trial CVac in three more cancer types
26 June, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has announced phase II trials for cancer treatment candidate CVac in pancreatic, colorectal and breast cancers.
GTG hails breast cancer risk detection study
25 June, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) says an Australian academic study supports the effectiveness of including genotypes used in its BREVAGen test to improve breast cancer risk assessment.
GTG signs on with seventh US PPO
20 June, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has reached an agreement with US PPO FedMed that will allow insurance claims for its BrevaGEN breast cancer risk test to be expedited for 40 million lives.
Compumedics finds funding for order backlog
14 June, 2013 by Dylan Bushell-EmblingCompumedics (ASX:CMP) has finally secured the short-term funding needed to help it process a significant order backlog for its diagnostics products.
Patrys’s antibody written up in melanoma journal
13 June, 2013 by Dylan Bushell-EmblingAn article summarising the early-stage development of Patrys’s PAT-SM6 as a melanoma treatment has been published in Melanoma Research.
Biosensors open a portal to improving cancer treatment
13 June, 2013Advanced technologies help researchers visualise cancer spreading and improve drug delivery.
Bionomics fills quota for renal cancer trial
12 June, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has completed enrolment for the first clinical trial involving a vascular disrupting agent - the company’s BNC105 candidate - with an mTOR inhibitor.
Patrys nabs NZ patent for cancer antibody
11 June, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has picked up a patent covering anticancer antibody PAT-LM1 in a second market - New Zealand.
Award for excellence in health and medical research
11 June, 2013An infectious diseases researcher has been recognised for his dedication to patients and biomedical research.
Sunscreen each day keeps ageing skin at bay
04 June, 2013Australian research has found that daily use of broad-spectrum sunscreen slows the ageing process of skin, as well as preventing skin cancer.
Newcastle Uni researchers target bowel disease
03 June, 2013 by Dylan Bushell-EmblingResearchers from the University of Newcastle, the University of Colorado and Aerpio Therapeutics have demonstrated the potential for a new class of drugs to treat inflammatory bowel disease.
Biotron to present HIV trial data at IAS 2013
31 May, 2013 by Dylan Bushell-EmblingBiotron (ASX:BIT) will present data from its phase IIa trial of BIT225 in HIV at IAS 2013 in Malaysia.
